289 related articles for article (PubMed ID: 17045195)
1. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
Mikalsen T; Gerits N; Moens U
Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
[TBL] [Abstract][Full Text] [Related]
2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
3. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
4. Kinases as targets in the treatment of solid tumors.
Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
[TBL] [Abstract][Full Text] [Related]
5. Integrin-linked kinase: a cancer therapeutic target unique among its ILK.
Hannigan G; Troussard AA; Dedhar S
Nat Rev Cancer; 2005 Jan; 5(1):51-63. PubMed ID: 15630415
[TBL] [Abstract][Full Text] [Related]
6. Key cancer cell signal transduction pathways as therapeutic targets.
Bianco R; Melisi D; Ciardiello F; Tortora G
Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
[TBL] [Abstract][Full Text] [Related]
7. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
8. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
12. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer].
Leirdal M; Sioud M
Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574
[TBL] [Abstract][Full Text] [Related]
13. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies.
Kondapalli L; Soltani K; Lacouture ME
J Am Acad Dermatol; 2005 Aug; 53(2):291-302. PubMed ID: 16021125
[TBL] [Abstract][Full Text] [Related]
14. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
[No Abstract] [Full Text] [Related]
15. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction: multiple pathways, multiple options for therapy.
Heldin CH
Stem Cells; 2001; 19(4):295-303. PubMed ID: 11463949
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
[TBL] [Abstract][Full Text] [Related]
18. [Protein tyrosine kinase inhibitors in cancer therapy].
Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
[TBL] [Abstract][Full Text] [Related]
19. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors in pediatric malignancies.
Skolnik JM; Adamson PC
Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]